Springview Capital Management's Q2 2023 letter highlighted Haleon (LSE:HLN, Financial) as a new core position. The UK-based consumer health company, valued at $38 billion, owns well-known brands such as Advil and Sensodyne. Despite its high-quality business and growth prospects, Haleon trades at a discount to peers like P&G and Colgate. The fund attributes this valuation disconnect to temporary overhangs, including share sales by former parent companies and Zantac litigation concerns.
"The opportunity to buy into an above-average business like HLN at a below-average multiple is due to three investor hangups, in our view..." — Springview Capital Management, Q2 2023 Fund Letter
Read full letter at gurufocus Springview Capital Management 2023 Q2 page.
